MG001 Phase 1 Trial Protocol Confirmed: 32 Volunteers, 25–100 mg Doses, Kansas Dosing Starts September

Why it matters

The public registry record for NCT07204171 now shows the full protocol: exactly what doses, what safety endpoints, and what the trial was never designed to answer. Primary results are expected by March 2027 — the first controlled human pharmacokinetic and safety data for purified mitragynine.

The big picture

Federal agencies are moving on parallel tracks simultaneously: the DEA has targeted concentrated synthetic 7-OH products for Schedule I placement while NIDA is funding Phase 1 human testing of mitragynine as a potential OUD treatment. The two tracks are not contradictory — the DEA action covers synthetic derivatives above a concentration threshold; the trial tests a different alkaloid at controlled doses. Still, the contrast is striking as enforcement tightens and research opens at the same time.

Key findings

• Trial NCT07204171 is sponsored by NIDA and conducted at Altasciences Clinical Kansas in Overland Park; start date September 2026, primary completion March 2027
• 32 healthy adult volunteers ages 18–65, randomized 6:2 drug-to-placebo in four cohorts of eight
• Single ascending doses: 25 mg, 50 mg, 75 mg, and 100 mg of pharmaceutical-grade mitragynine (MG001); each cohort receives one dose level only
• Primary endpoint: treatment-emergent adverse events tracked via ECG/QTcF monitoring and respiratory function (the two central safety concerns in the kratom debate)
• Volunteers remain in clinic under continuous observation for four days, returning on Day 7 for follow-up blood draw
• Phase 1 will not test efficacy for opioid withdrawal — that question requires separate Phase 2 and 3 trials not yet announced

What they say

"For an industry that has spent years arguing about kratom in the absence of controlled human data on its main alkaloid, the most consequential development of this month may not be a scheduling order at all. It may be 32 volunteers in a clinic in Kansas," Kratom.news reported, adding that Phase 1 is "the moment the argument stops being fought entirely with secondhand data."

Bottom line

The MG001 Phase 1 trial begins September 2026 with 32 volunteers at 25–100 mg doses, targeting cardiac and respiratory safety data — with results expected March 2027.